Abivax SA Sponsored ADR (NASDAQ:ABVX) Receives $134.75 Average Price Target from Brokerages

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $134.75.

Several research firms have recently issued reports on ABVX. Guggenheim reiterated a “buy” rating and issued a $175.00 target price on shares of Abivax in a research note on Thursday, December 18th. Morgan Stanley raised their price target on shares of Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, January 9th. Truist Financial set a $140.00 price objective on shares of Abivax in a research report on Monday, November 24th. Citizens Jmp increased their price objective on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research note on Tuesday, December 16th. Finally, BTIG Research reissued a “buy” rating and set a $150.00 target price on shares of Abivax in a research report on Wednesday, February 25th.

Institutional Trading of Abivax

A number of hedge funds have recently bought and sold shares of the business. TCG Crossover Management LLC grew its stake in Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after purchasing an additional 1,055,000 shares during the period. UBS Group AG raised its stake in shares of Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares during the period. Darwin Global Management Ltd. raised its stake in shares of Abivax by 0.4% during the 4th quarter. Darwin Global Management Ltd. now owns 3,178,501 shares of the company’s stock worth $439,714,000 after purchasing an additional 14,000 shares during the period. Morgan Stanley boosted its holdings in shares of Abivax by 114.3% in the 4th quarter. Morgan Stanley now owns 3,151,994 shares of the company’s stock worth $425,062,000 after buying an additional 1,681,277 shares during the last quarter. Finally, Vestal Point Capital LP grew its position in Abivax by 90.0% during the fourth quarter. Vestal Point Capital LP now owns 1,900,000 shares of the company’s stock valued at $256,224,000 after buying an additional 900,000 shares during the period. 47.91% of the stock is currently owned by institutional investors.

Abivax Stock Performance

Shares of Abivax stock opened at $109.61 on Thursday. Abivax has a 52 week low of $4.77 and a 52 week high of $148.83. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average price of $120.63 and a 200-day moving average price of $108.07. The company has a market cap of $8.67 billion, a PE ratio of -26.22 and a beta of 1.01.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The company had revenue of ($4.92) million during the quarter. Equities analysts anticipate that Abivax will post -2.83 earnings per share for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.